Global licensing Waymade has a history of licensing and distributing generic and branded pharmaceuticals across multiple regions via their Sovereign and Atnahs platforms, indicating potential for partnerships in licensing, co marketing, and regional distribution deals with manufacturers seeking European, Middle Eastern, and Asia Pacific access.

Expansion-ready footprint With a diversified portfolio and international footprint spanning 27 countries through Atnahs, coupled with a track record of acquisitions and growth, there are opportunities to upsell manufacturing agreements, contract development and manufacturing services, or regional supply contracts with hospitals, wholesalers, and retail chains.

Invested infrastructure Recent investments in a state of the art laboratory and temperature controlled facilities signal capacity to support advanced formulation, stability testing, and quality assured production, enabling sales pitches for CDMO services, regulatory compliance support, and scalable manufacturing capacity.

Strategic partnerships The 2023 collaboration with Whampoa Digital and the parent group’s family office structure suggest openness to strategic partnerships and venture style collaborations that can be leveraged to co invest in new product lines, digital distribution initiatives, or Web3 enabled supply chain solutions.

SMB to mid market focus Waymade operates with mid sized scale and a broad distribution network in pharmacies, hospitals, and wholesalers, presenting a fit for mid market supplier agreements, white label opportunities, or portfolio expansion through private label partnerships targeted at regional players seeking reliable generic and branded products.